How lower-middle-market founders/sellers should weigh a PE platform against a strategic buyer when weighing medtech M&A.
If you supply, mold, machine, assemble, or package for a medical device OEM, at least one of your competitors has probably changed ownership recently — and the outsourcing base looks materially different than it did a few years ago. Join MedWorld Advisors to learn who's doing the buying, why certain CDMOs command higher valuations than other medtech suppliers, and what it means to compete against consolidated, well-capitalized platforms.
MedWorld Advisors served as exclusive sell-side advisor to Unitron Group B.V. on its sale to Nolato AB. The combination brings Unitron's manufacturing capability into Nolato's global medtech platform — a strong outcome for shareholders and a strong home for the business.
While AI is a fantastic tool to use during M&A transactions, it doesn’t replace the situational intelligence provided by human transaction advisors.
The 2026 Top 10 Companies list is less a ranking than a map of an industry transforming itself in public.
Capability-building medtech acquisitions are more relevant to the market than headline-grabbing transformational ones. Read more in our column, MedTech Mindset, in Today’s Medical Developments Magazine.
The most important takeaway from the 2026 MPO Top 30 report is not embedded in any one transaction but rather the pattern among the ranked firms.
The conversation at FMMC mirrored some of the discussions taking place in deal rooms this year.
Medtech companies must assess where artificial intelligence creates value at each stage of the product lifecycle.
Two of medtech outsourcing’s most established names changed owners on the same Monday in August. Read about the deals in our recent column in MPO Magazine.